期刊文献+

蛋白酶体抑制剂联合亚砷酸对白血病细胞株NB4的凋亡诱导效应

Enhanced apoptosis-inducing effect of arsenic trioxide on leukemia cell lines NB4 by proteasomes inhibiter
原文传递
导出
摘要 目的 观察蛋白酶体抑制剂硼替佐米(BOR)联合急性早幼粒细胞白血病(APL)凋亡诱导剂亚砷酸(ATO)对NB4细胞株的作用.方法 BOR单独及联合ATO作用于NB4细胞,应用MTT法观察细胞的生长抑制效应;流式细胞术检测细胞周期变化及凋亡率;RT-PCR方法检测survivin mRNA的表达.结果 MTT法显示BOR对NB4细胞具有生长抑制作用,且能增强ATO对细胞的杀伤作用;流式细胞仪检测可见明显凋亡峰及G2/M期细胞周期阻滞;RT-PCR检测发现两药单独应用均能下调survivin mRNA的表达,联合作用时具相加效应.结论 ATO与BOR联合作用较单独作用有更强的细胞杀伤及诱导细胞凋亡活性,细胞周期G2/M期的阻滞及survivin mRNA表达的下降是蛋白酶体抑制剂及亚砷酸对白血病细胞株联合诱导凋亡的可能机制. Objeetive To observe NB4 cells that is treated with both ATO and BOR.Methods MTT assay demonstrated that NB4 cell lines,growth inhibiting effect after interfered with BOR alone or BOR plus ATO.Flow cytometry detect cell cycle and apoptosis.RT-PCR method detect the expression of survivin mRNA.Results MTT assay showed depressant effect by BOR.BOR can strengthen cells,lethal effect by ATO.Flow cytometry investigate obvious apoptosis and cycle blockage of G2/M stage.RT-PCR discover that ATO or BOR can downregulate the expression of survivin mRNA alone,there is an additional effect if used them at the same time.Conclusion Combination of BOR and ATO have stronger inflictive and apoptosisinducing activity.The blockage of G2/M stage and degression of survivin mRNA is a possible mechanism that leads to cell apoptosis treated with BOR and ATO.
出处 《肿瘤研究与临床》 CAS 2008年第4期231-233,236,共4页 Cancer Research and Clinic
  • 相关文献

参考文献9

  • 1Cai X,Shen YL,Zhu Q. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia[J].Leukemia:Official Journal of the Leukemia Society of America Leukemia Research Fund U K,2000,(02):262-270.doi:10.1038/sj.leu.2401650.
  • 2扶云碧,孙启鑫,孟凡义,谢军,周光飚.蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株 HL60凋亡的机制研究[J].中华医学杂志,2006,86(34):2413-2416. 被引量:14
  • 3Horton TM,Gannavarapu A,Blaney SM. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro[J].Cancer Chemotherapy and Pharmacology,2006,(01):13-23.doi:10.1007/s00280-005-0135-z.
  • 4Daj Y,Rahmanj M,Pei XY. Bortezomib and flavopifidol interact synerglstically to induce apoptosis in chronic myeloidleukemia cells resistant to imatinib mesylate throush both Bcr/Abl-dependent and-independent mechanisms[J].Blood,2004,(02):509-518.doi:10.1182/blood-2003-12-4121.
  • 5Hideshima T. The proteasome inhibitor ps-341 inhibits growth,induce apoptosis,and overcomes drug resistance in human multiple myeloma cells[J].CANCER RESEARCH,2001,(07):3071-3076.
  • 6Frankel A,Man S,Elliott P. Lack of muhicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341[J].Clinical Cancer Research,2000,(09):3719-3728.
  • 7兰雨,张学敏,杨平地,沈倍奋.蛋白酶体抑制剂可增加足叶乙甙对白血病细胞系M-07e和TF-1的凋亡诱导效应[J].中国实验血液学杂志,2003,11(5):485-489. 被引量:2
  • 8狄春红,顾少华,谭晓华,仙玲,和桂芬,季超能,杨磊.As_2O_3对NB4细胞增殖及凋亡的影响[J].中国公共卫生,2006,22(9):1134-1136. 被引量:8
  • 9Olie RA,Simoes-Wust AP,Baumann B. A novel antisense oligonu-eleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy[J].Cancer Research,2000,(11):2805-2809.

二级参考文献33

  • 1FeiGAO,JingYI,JingQiYUAN,GuiYingSHI,XueMingTANG.The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species[J].Cell Research,2004,14(1):81-85. 被引量:21
  • 2江千里,孟凡义.肿瘤治疗新靶点:蛋白酶体抑制剂的基础和临床应用[J].中华医学杂志,2005,85(29):2085-2088. 被引量:3
  • 3Hirsch T, Dallaporta B, Zamzami N, et al. Proteasome activation occurs at an early, premitochondrial step of thymocyte apoptosis. J Immunol, 1998; 161:35-40.
  • 4Tabata M, Tabata R, Grabowski DR, et al. Roles of NF-кB and 26 S proteasome in apoptotic cell death induced by topoisomerase Ⅰ and Ⅱ poisons in human nonsmall cell lung carcinoma. J Biol Chem,2001 ; 276:8029 - 8036.
  • 5Fadeel B, Hassan Z, Hellstrom-Lindberg E, et al. Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells. Leukemia, 1999; 13: 719- 728.
  • 6Cheng EH, Kirsch DC, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science, 1997; 278:1966 - 1968.
  • 7Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis.Cell Death Differ, 1999; 6:303 -313.
  • 8Sayers TJ, Brooks/kiD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 2003; [epub ahead of print].
  • 9Cory AH, CoryJG. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NF-kappaB activation, on drug-resistant mouse leukemia L1210 cells. Anticancer Res, 2002; 22(6C) : 3805 - 3809.
  • 10Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apopto6is for primary human leukemic stem cells. Proc Natl Acad Sci USA, 2002; 99: 16220- 16225.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部